These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2960431)

  • 21. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
    Ogawa N
    Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
    Jellinger K
    J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine".
    Lang AE
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):474-82. PubMed ID: 3315148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Parkinson's disease with lergotrile mesylate.
    Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
    JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Marsden CD
    Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes].
    Szczudlik A; Rudzińska M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S6-9. PubMed ID: 17941452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further studies with pergolide in Parkinson disease.
    Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E; Nelson J
    Neurology; 1982 Oct; 32(10):1181-4. PubMed ID: 6889703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
    Schneider E; Baas H; Fischer PA; Japp G
    J Neurol; 1985; 232(1):24-8. PubMed ID: 3998771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesulergine in early Parkinson's disease: a double blind controlled trial.
    Dupont E; Mikkelsen B; Jakobsen J
    J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.